Navigation Links
Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint

with Hepsera for a median of 49 weeks up to a maximum of 240 weeks. Changes in serum creatinine were observed very commonly in patients pre- and post-transplantation with lamivudine-resistant liver disease and multiple risk factors for changes in renal function who were treated with Hepsera for up to 129 weeks, with a median time on treatment of 19 and 56 weeks, respectively. Clinical and laboratory evidence of exacerbations of hepatitis have occurred after discontinuation of treatment with antiviral therapies for hepatitis B, including Hepsera. Special warnings and precautions for use are included in the package insert regarding monitoring of renal function, post-treatment exacerbations of hepatitis, and the occurrence of lactic acidosis and severe hepatomegaly with steatosis. Dosing instructions for patients with underlying renal impairment and for patients co-infected with HIV are also provided in the package insert, which is available for download online at www.hepsera.com.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia. For more information on Gilead Sciences, please visit the company's website at www.gilead.com or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including risks related to Gilead's ability to successfully commercialize tenofovir DF for chronic hepatitis B. For example, the FDA may not approve tenofovir DF for the treatment of chronic hepatitis B in the United States, and marketing approval, i
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:3/27/2015)... 27, 2015 /CNW Telbec/ - Russell Williams , ... Companies (Rx&D), welcomes the 2015-2016 Quebec Budget, noting the ... on the biopharmaceutical industry. However, the association is concerned ... "We commend the government,s intent to strive for a ... to promote Quebec,s economic development ...
(Date:3/27/2015)... The Temple Health & Bioscience District (THBD) today announced it ... South First St. in the Temple Medical and Education District ... of Temple to receive funding for redevelopment. Located ... Health Care System, the new facility will enable THBD to ... life science companies. Temple ...
(Date:3/27/2015)... -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH) is launching ... Available in both small (6mm) and large ... System from Zimmer is a modular system that offers surgeons ... XtraFix System allows surgeons to eliminate steps, as well ... in saved time, costs and overall team effort. ...
Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2Zimmer Debuts New Modular External Fixation System 2Zimmer Debuts New Modular External Fixation System 3
... RDEA594 Data to Be Presented at the 2008 Annual European Congress of, Rheumatology ... Phase 1 Human Study of RDEA594 Planned in Second Half of ... ... Biosciences, Inc.,(Nasdaq: RDEA ) today announced the identification of its lead development,candidate ...
... filing anticipated in 1Q 2009 -, PRINCETON, ... ) has nominated PSI-7851 as a lead development ... (HCV). PSI-7851 is a proprietary,nucleotide analogue polymerase inhibitor ... Practice (GLP) animal toxicity studies required for,submission of ...
Cached Medicine Technology:Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 2Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 3Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 4Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 5Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C 2Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C 3
(Date:3/28/2015)... 2015 With more than 4,500 ... of osteoporosis, osteoarthritis and musculoskeletal diseases gathered here ... be the first time in the 17-year history ... the hot-button topic is an emerging non-pharmaceutical protocol ... scientific principles of Wolff’s law, osteogenic loading at ...
(Date:3/28/2015)... 2015 India Network visitor health ... available to all visitors who purchase the plan before ... are encouraged to purchase the insurance program as soon ... proper coverage for pre-existing medical conditions. Parents and grandparents ... medical conditions with serious consequences to their health. Many ...
(Date:3/28/2015)... One in three young athletes who ... today at the American Orthopaedic Society for Sports Medicine’s ... long term success of surgery for patients aged 18 ... from 242 patients who underwent ACL reconstruction between 1993 ... FRACS, from North Sydney Orthopaedic and Sports Medicine Centre. ...
(Date:3/28/2015)... Genomic medicine experts have sequenced the genomes ... first time, key information for understanding and treating this ... posted story on the Surviving Mesothelioma website. ... the British Columbia Cancer Agency, and PhenoPath lab in ... alterations and mutations that can lead to peritoneal ...
(Date:3/28/2015)... Healthpointe’s otolaryngologists, medical practitioners who attend ... disorders, are now offering a wide variety of treatments ... characterized by the presence of phantom sounds or ringing ... is a prevalent symptom that can arise due to ... tinnitus can impede a person’s quality of life. , ...
Breaking Medicine News(10 mins):Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2
... study finds , FRIDAY, Aug. 21 (HealthDay News) -- Imagine ... they take root in the brain. , That,s the promise ... -- assuming the findings can be applied to humans, that ... Rio Grande do Sul, Brazil, with colleagues at the University ...
... ... loss. , ... (PRWEB) August 22, 2009 -- Over 50 million American men suffer from hair loss. With ... and male pattern hair loss sufferer, Kevin Nalty (a.k.a. "Nalts") to raise awareness about hair ...
... , WINTER PARK, Fla., Aug. 17 ... Corporation clearance of its new MRidium 3860+ MRI Infusion System ... for Sedation, Critical Care, and Cardiac Patients to date has ... SpO2 being typically not designed to be integrated and functional ...
... , , SOLON, Ohio, Aug. ... U.S. marketplace, Nestle USA is pleased to announce that NESTLE TOLL ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20090818/SF63053-a ) , (Photo: http://www.newscom.com/cgi-bin/prnh/20090818/SF63053-b ) ... retail partners and consumers to identify the new batch of cookie ...
... In the first in a series on evaluating eHealth ... Aziz Sheikh and Lorraine Catwell from The University of ... and discuss the importance of evaluating the widespread investments ... care. Funding: This work was supported by a ...
... over health care reform continues to unfold in town hall ... Harvard researchers has found that taxing job-based health benefits would ... regressivity of taxing employer-paid health insurance," appears in the August ... Medicine . It was written by Drs. David Himmelstein and ...
Cached Medicine News:Health News:Dopamine Lets Bad Experiences Linger 2Health News:Dopamine Lets Bad Experiences Linger 3Health News:Vlogging For Hair: YouTube Star 'Nalts' Promotes Hair Loss Awareness with Dr. Alan Bauman 2Health News:Vlogging For Hair: YouTube Star 'Nalts' Promotes Hair Loss Awareness with Dr. Alan Bauman 3Health News:Vlogging For Hair: YouTube Star 'Nalts' Promotes Hair Loss Awareness with Dr. Alan Bauman 4Health News:IRadimed Announces 510K Clearance of the New Non-Magnetic MRidium(TM) MRI IV Pump with Integrated Masimo SET(R) SpO2 Monitoring 2Health News:IRadimed Announces 510K Clearance of the New Non-Magnetic MRidium(TM) MRI IV Pump with Integrated Masimo SET(R) SpO2 Monitoring 3Health News:IRadimed Announces 510K Clearance of the New Non-Magnetic MRidium(TM) MRI IV Pump with Integrated Masimo SET(R) SpO2 Monitoring 4Health News:Updated With Photos: NESTLE(R) TOLL HOUSE(R) Re-launches With 'New Batch' Label 2Health News:eHealth interventions need to be continuously evaluated 2Health News:Harvard study reveals taxing job-based health benefits would hit working families hardest 2
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
This dissector offers dual-action jaws, which are long, tapered, and angled 30 to simplify even difficult laparoscopic dissection....
Medicine Products: